Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
| ▸ | HRAS | P01112 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128062 | 1.00 | TACR2 (0.45) | TACR2HRASTP53MDM2L3MBTL1 | |
| SCHEMBL24378386 | 0.88 | TP53 (0.55) | TACR2TP53MDM2MDM4HSP90AA1 | |
| SCHEMBL13296082 | 0.88 | TP53 (0.55) | TACR2TP53MDM2MDM4HSP90AA1 | |
| SCHEMBL7774709 | 0.88 | MAPK1 (0.50) | TACR2HRASTP53MDM2L3MBTL1 | |
| SCHEMBL13296098 | 0.84 | TP53 (0.55) | TACR2TP53MDM2MDM4HSP90AA1 | |
| SCHEMBL13491610 | 0.84 | MAPK1 (0.48) | TACR2HRASTP53MDM2L3MBTL1 | |
| SCHEMBL7152991 | 0.83 | L3MBTL1 (0.53) | TP53MDM2L3MBTL1MDM4HSP90AA1 | |
| SCHEMBL1149280 | 0.82 | HRAS (0.47) | TACR2HRASL3MBTL1LGALS3LMNA | |
| SCHEMBL6553315 | 0.82 | LGALS3 (0.47) | HRASTP53MDM2L3MBTL1LGALS3 | |
| SCHEMBL7233754 | 0.82 | L3MBTL1 (0.44) | TACR2HRASTP53MDM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8062641-B2 | Immunogens for meningitidis-A vaccines | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20090304734-A1 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304734-A1 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | MAN2A1, ALG1, MNS1 | TACR2 4518/4885HRAS 4727/4885TP53 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.